{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:40:06Z","timestamp":1772642406512,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s12282-026-01833-8","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T06:13:43Z","timestamp":1770790423000},"page":"485-498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["FGFR4 and HER2 co-expression is associated with the proinflammatory tumor microenvironment in HR\u2009+\u2009breast cancer"],"prefix":"10.1007","volume":"33","author":[{"given":"Yike","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longyun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changbin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shafei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4787-2925","authenticated-orcid":false,"given":"Zhiyong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"1833_CR1","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nrc2780","volume":"10","author":"N Turner","year":"2010","unstructured":"Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10:116\u201329.","journal-title":"Nat Rev Cancer"},{"key":"1833_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrd2792","volume":"8","author":"A Beenken","year":"2009","unstructured":"Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009;8:235\u201353.","journal-title":"Nat Rev Drug Discov"},{"key":"1833_CR3","doi-asserted-by":"publisher","first-page":"6443","DOI":"10.1158\/1078-0432.CCR-19-0138","volume":"25","author":"JZ Drago","year":"2019","unstructured":"Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, et al. FGFR1 amplification mediates endocrine resistance but retains TORC sensitivity in metastatic hormone receptor-positive (HR(+)) breast cancer. Clin Cancer Res. 2019;25:6443\u201351.","journal-title":"Clin Cancer Res"},{"key":"1833_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09068-2","volume":"10","author":"L Formisano","year":"2019","unstructured":"Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, et al. Aberrant FGFR signaling mediates resistance to CDK4\/6 inhibitors in ER+ breast cancer. Nat Commun. 2019;10:1373.","journal-title":"Nat Commun"},{"key":"1833_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092713","volume":"12","author":"M Braun","year":"2020","unstructured":"Braun M, Piasecka D, Tomasik B, Mieczkowski K, Stawiski K, Zielinska A, et al. Hormonal receptor status determines prognostic significance of FGFR2 in invasive breast carcinoma. Cancers. 2020;12:2713.","journal-title":"Cancers"},{"key":"1833_CR6","doi-asserted-by":"publisher","first-page":"86011","DOI":"10.18632\/oncotarget.13322","volume":"7","author":"D Piasecka","year":"2016","unstructured":"Piasecka D, Kitowska K, Czaplinska D, Mieczkowski K, Mieszkowska M, Turczyk L, et al. Fibroblast growth factor signalling induces loss of progesterone receptor in breast cancer cells. Oncotarget. 2016;7:86011\u201325.","journal-title":"Oncotarget"},{"key":"1833_CR7","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1158\/1078-0432.CCR-16-2287","volume":"23","author":"AB Hanker","year":"2017","unstructured":"Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, et al. HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clin Cancer Res. 2017;23:4323\u201334.","journal-title":"Clin Cancer Res"},{"key":"1833_CR8","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1158\/1078-0432.CCR-12-2736","volume":"19","author":"TM Zaid","year":"2013","unstructured":"Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, et al. Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clin Cancer Res. 2013;19:809\u201320.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1833_CR9","doi-asserted-by":"publisher","first-page":"e36713","DOI":"10.1371\/journal.pone.0036713","volume":"7","author":"DM French","year":"2012","unstructured":"French DM, Lin BC, Wang M, Adams C, Shek T, Hotzel, K, et al. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS ONE. 2012;7(5):e36713.","journal-title":"PLoS ONE"},{"key":"1833_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cells8091092","volume":"8","author":"G Jomrich","year":"2019","unstructured":"Jomrich G, Hudec X, Harpain F, Winkler D, Timelthaler G, Mohr T, et al. Expression of FGF8, FGF18, and FGFR4 in gastroesophageal adenocarcinomas. Cells. 2019;8:1092.","journal-title":"Cells"},{"key":"1833_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107590","volume":"214","author":"KM Levine","year":"2020","unstructured":"Levine KM, Ding K, Chen L, Oesterreich S. FGFR4: a promising therapeutic target for breast cancer and other solid tumors. Pharmacol Ther. 2020;214:107590.","journal-title":"Pharmacol Ther"},{"key":"1833_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202308711","volume":"11","author":"F Chen","year":"2024","unstructured":"Chen F, Zhang K, Wang M, He Z, Yu B, Wang X, et al. VEGF-FGF Signaling Activates Quiescent CD63(+) Liver Stem Cells to Proliferate and Differentiate. Adv Sci (Weinh). 2024;11:e2308711.","journal-title":"Adv Sci (Weinh)"},{"key":"1833_CR13","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1111\/febs.16768","volume":"290","author":"L Zhou","year":"2023","unstructured":"Zhou L, Ou S, Liang T, Li M, Xiao P, Cheng J, et al. MAEL facilitates metabolic reprogramming and breast cancer progression by promoting the degradation of citrate synthase and fumarate hydratase via chaperone-mediated autophagy. FEBS J. 2023;290:3614\u201328.","journal-title":"FEBS J"},{"key":"1833_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-022-00992-4","volume":"15","author":"WP He","year":"2022","unstructured":"He WP, Yang GP, Yang ZX, Shen HW, You ZS, Yang GF. Maelstrom promotes tumor metastasis through regulation of FGFR4 and epithelial-mesenchymal transition in epithelial ovarian cancer. J Ovarian Res. 2022;15:55.","journal-title":"J Ovarian Res"},{"key":"1833_CR15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1677\/ERC-07-0080","volume":"15","author":"D Meijer","year":"2008","unstructured":"Meijer D, Sieuwerts AM, Look MP, van Agthoven T, Foekens JA, Dorssers LC. Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer. Endocr Relat Cancer. 2008;15:101\u201311.","journal-title":"Endocr Relat Cancer"},{"key":"1833_CR16","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1172\/JCI130323","volume":"130","author":"S Garcia-Recio","year":"2020","unstructured":"Garcia-Recio S, Thennavan A, East MP, Parker JS, Cejalvo JM, Garay JP, et al. FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. J Clin Invest. 2020;130:4871\u201387.","journal-title":"J Clin Invest"},{"key":"1833_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188595","volume":"1876","author":"A Servetto","year":"2021","unstructured":"Servetto A, Formisano L, Arteaga CL. FGFR signaling and endocrine resistance in breast cancer: challenges for the clinical development of FGFR inhibitors. Biochim Biophys Acta Rev Cancer. 2021;1876:188595.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1833_CR18","doi-asserted-by":"publisher","first-page":"C343","DOI":"10.1152\/ajpcell.00109.2021","volume":"321","author":"KM Turner","year":"2021","unstructured":"Turner KM, Yeo SK, Holm TM, Shaughnessy E, Guan JL. Heterogeneity within molecular subtypes of breast cancer. Am J Physiol Cell Physiol. 2021;321:C343-343C354.","journal-title":"Am J Physiol Cell Physiol"},{"key":"1833_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2912","volume":"13","author":"AE Place","year":"2011","unstructured":"Place AE, Jin Huh S, Polyak K. The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res. 2011;13:227.","journal-title":"Breast Cancer Res"},{"key":"1833_CR20","doi-asserted-by":"publisher","DOI":"10.36922\/cp.2633","volume":"6","author":"K Vignesh","year":"2024","unstructured":"Vignesh K, Thangamalar P. Regulatory role of lncRNA MALAT1 and miR-150-3p interaction in breast cancer progression and therapeutic implications. Cancer Plus. 2024;6:2633.","journal-title":"Cancer Plus"},{"key":"1833_CR21","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.7150\/thno.68972","volume":"12","author":"Y Wu","year":"2022","unstructured":"Wu Y, Yi Z, Li J, Wei Y, Feng R, Liu J, et al. FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts. Theranostics. 2022;12:4564\u201380.","journal-title":"Theranostics"},{"key":"1833_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41416-024-02658-y","volume":"131","author":"M Braun","year":"2024","unstructured":"Braun M, Piasecka D, Sadej R, Romanska HM. FGFR4-driven plasticity in breast cancer progression and resistance to therapy. Br J Cancer. 2024;131:11\u201322.","journal-title":"Br J Cancer"},{"key":"1833_CR23","doi-asserted-by":"publisher","DOI":"10.25259\/Cytojournal_107_2024","volume":"21","author":"X Liu","year":"2024","unstructured":"Liu X, Zhang G, Zhao L. Detection of transmembrane protein 100 in breast cancer: correlation with malignant progression and chemosensitivity. Cytojournal. 2024;21:65.","journal-title":"Cytojournal"},{"key":"1833_CR24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13046-023-02659-4","volume":"42","author":"Y Yang","year":"2023","unstructured":"Yang Y, Zhang Y, Cao J, Su Z, Li F, Zhang P, et al. FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling. J Exp Clin Cancer Res. 2023;42:96.","journal-title":"J Exp Clin Cancer Res"},{"key":"1833_CR25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.36922\/arnm.5132","volume":"3","author":"L Lukas","year":"2025","unstructured":"Lukas L, Ri Han H, T. Roussos Torres E, G. Baugh A, Bell O, C. Ye J, et al. Targeting EZH2 to mitigate immune checkpoint resistance in ARID1A-deficient triple-negative breast cancer. Advances in Radiotherapy & Nuclear Medicine. 2025;3:28.","journal-title":"Advances in Radiotherapy & Nuclear Medicine"},{"key":"1833_CR26","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1039\/D4CC06510G","volume":"61","author":"C Zhao","year":"2025","unstructured":"Zhao C, Song W, Wang J, Tang X, Jiang Z. Immunoadjuvant-functionalized metal-organic frameworks: synthesis and applications in tumor immune modulation. Chem Commun (Camb). 2025;61:1962\u201377.","journal-title":"Chem Commun (Camb)"},{"key":"1833_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2025.101322","volume":"15","author":"W You","year":"2025","unstructured":"You W, Zhou Z, Li Z, Yan J, Wang Y. From foe to friend: rewiring oncogenic pathways through artificial selenoprotein to combat immune-resistant tumor. J Pharm Anal. 2025;15:101322.","journal-title":"J Pharm Anal"},{"key":"1833_CR28","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40005-025-00731-z","volume":"55","author":"H Yuan","year":"2025","unstructured":"Yuan H, Chen Y, Hu Y, Li Y, Zhang H, Zhang S, et al. Disulfide bond-driven nanoassembly of lipophilic epirubicin prodrugs for breast cancer therapy. J Pharm Investig. 2025;55:889\u2013902.","journal-title":"J Pharm Investig"},{"key":"1833_CR29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3923\/ijp.2023.531.536","volume":"19","author":"HM Kaplan","year":"2023","unstructured":"Kaplan HM, Mete S. Haplophyllum buxbaumii induces apoptosis via MAPK and AKT\/mTOR pathways in MCF-7 breast cancer cell line. Int J Pharmacol. 2023;19:531\u20136.","journal-title":"Int J Pharmacol"},{"key":"1833_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14489","volume":"30","author":"WW Duan","year":"2024","unstructured":"Duan WW, Yang LT, Liu J, Dai ZY, Wang ZY, Zhang H, et al. A TGF-\u03b2 signaling-related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response. CNS Neurosci Ther. 2024;30:e14489.","journal-title":"CNS Neurosci Ther"},{"key":"1833_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/imm.13793","volume":"173","author":"ZB Wang","year":"2024","unstructured":"Wang ZB, Zhang X, Fang C, Liu XT, Liao QJ, Wu N, et al. Immunotherapy and the ovarian cancer microenvironment: Exploring potential strategies for enhanced treatment efficacy. Immunology. 2024;173:14\u201332.","journal-title":"Immunology"},{"issue":"4","key":"1833_CR32","doi-asserted-by":"publisher","first-page":"371","DOI":"10.14744\/ejmo.2023.80452","volume":"7","author":"HJ Yi Leong","year":"2023","unstructured":"Yi Leong HJ. Identification of Potentially Therapeutic Target Genes in Metastatic Breast Cancer via Integrative Network Analysis. Eurasian J Medicine and Oncology. 2023;7(4):371\u201387.","journal-title":"Eurasian J Medicine and Oncology."},{"key":"1833_CR33","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1109\/TCBB.2020.2973148","volume":"18","author":"X Li","year":"2021","unstructured":"Li X, Xiang J, Wang J, Li J, Wu FX, Li M. FUNMarker: fusion network-based method to identify prognostic and heterogeneous breast cancer biomarkers. IEEE ACM Trans Comput Biol Bioinform. 2021;18:2483\u201391.","journal-title":"IEEE ACM Trans Comput Biol Bioinform"},{"key":"1833_CR34","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13046-024-02983-3","volume":"43","author":"TY Lin","year":"2024","unstructured":"Lin TY, Jia JS, Luo WR, Lin XL, Xiao SJ, Yang J, et al. ThermomiR-377-3p-induced suppression of Cirbp expression is required for effective elimination of cancer cells and cancer stem-like cells by hyperthermia. J Exp Clin Cancer Res. 2024;43:62.","journal-title":"J Exp Clin Cancer Res"},{"key":"1833_CR35","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1136\/ard-2024-225664","volume":"83","author":"D Nikolopoulos","year":"2024","unstructured":"Nikolopoulos D, Loukogiannaki C, Sentis G, Garantziotis P, Manolakou T, Kapsala N, et al. Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events. Ann Rheum Dis. 2024;83:1132\u201343.","journal-title":"Ann Rheum Dis"},{"key":"1833_CR36","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1833_CR37","first-page":"1739","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon A, Subramanian A, Pinchback R, Thorvaldsd\u00f3ttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics (Oxford, England). 2011;27:1739\u201340.","journal-title":"Bioinformatics (Oxford, England)"},{"key":"1833_CR38","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev A, Kotlov N, Nomie K, Svekolkin V, Gafurov A, Isaeva O, et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell. 2021;39:845-65.e7.","journal-title":"Cancer Cell"},{"key":"1833_CR39","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453\u20137.","journal-title":"Nat Methods"},{"key":"1833_CR40","unstructured":"The Cancer Genome Atlas Research Network. \"Comprehensive genomic characterization of breast invasive carcinoma (BRCA).\" TCGA. 2023. https:\/\/portal.gdc.cancer.gov\/ ."},{"issue":"11","key":"1833_CR41","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1038\/s41591-024-03215-z","volume":"30","author":"J Klughammer","year":"2024","unstructured":"Klughammer J, Abravanel DL, Asa S, Blosser TR, Goltsev Y, Cui Y, et al. A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features. Nat Med. 2024;30(11):3236\u201349.","journal-title":"Nat Med"},{"key":"1833_CR42","first-page":"3893","volume":"11","author":"W Gu","year":"2021","unstructured":"Gu W, Yang J, Wang Y, Xu J, Wang X, Du F, et al. Comprehensive identification of FGFR1-4 alterations in 5 557 Chinese patients with solid tumors by next-generation sequencing. Am J Cancer Res. 2021;11:3893\u2013906.","journal-title":"Am J Cancer Res"},{"key":"1833_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57419-z","volume":"16","author":"L Hohmann","year":"2025","unstructured":"Hohmann L, Sigurjonsdottir K, Campos AB, Nacer DF, Veerla S, Rosengren F, et al. Genomic characterization of the HER2-enriched intrinsic molecular subtype in primary ER-positive HER2-negative breast cancer. Nat Commun. 2025;16:2208.","journal-title":"Nat Commun"},{"key":"1833_CR44","first-page":"721","volume":"13","author":"JK Wang","year":"1996","unstructured":"Wang JK, Xu H, Li HC, Goldfarb M. Broadly expressed SNT-like proteins link FGF receptor stimulation to activators of Ras. Oncogene. 1996;13:721\u20139.","journal-title":"Oncogene"},{"key":"1833_CR45","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0092-8674(00)80252-4","volume":"89","author":"H Kouhara","year":"1997","unstructured":"Kouhara H, Hadari YR, Spivak-Kroizman T, Schilling J, Bar-Sagi D, Lax I, et al. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras\/MAPK signaling pathway. Cell. 1997;89:693\u2013702.","journal-title":"Cell"},{"key":"1833_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.936952","volume":"12","author":"C Yang","year":"2022","unstructured":"Yang C, Song D, Zhao F, Wu J, Zhang B, Ren H, et al. Comprehensive analysis of the prognostic value and immune infiltration of FGFR family members in gastric cancer. Front Oncol. 2022;12:936952.","journal-title":"Front Oncol"},{"key":"1833_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01761-7","volume":"22","author":"R Ruan","year":"2023","unstructured":"Ruan R, Li L, Li X, Huang C, Zhang Z, Zhong H, et al. Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF\/FGFR signaling in tumor microenvironment. Mol Cancer. 2023;22:60.","journal-title":"Mol Cancer"},{"key":"1833_CR48","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1016\/j.csbj.2022.07.029","volume":"20","author":"S Lu","year":"2022","unstructured":"Lu S, Hua J, Xu J, Wei M, Liang C, Meng Q, et al. Turning towards nonimmunoreactive tumors: evaluation of cancer-associated fibroblasts enables prediction of the immune microenvironment and treatment sensitivity in pancreatic cancer. Comput Struct Biotechnol J. 2022;20:3911\u201323.","journal-title":"Comput Struct Biotechnol J"},{"key":"1833_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s44276-024-00118-x","volume":"3","author":"JR Hecht","year":"2025","unstructured":"Hecht JR, Michot JM, Bajor D, Patnaik A, Chung KY, Wang J, et al. CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced\/metastatic solid tumours. BJC Rep. 2025;3:10.","journal-title":"BJC Rep"},{"key":"1833_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00748-4","volume":"13","author":"F Du","year":"2025","unstructured":"Du F, Wang G, Dai Q, Huang J, Li J, Liu C, et al. Targeting novel regulated cell death: disulfidptosis in cancer immunotherapy with immune checkpoint inhibitors. Biomark Res. 2025;13:35.","journal-title":"Biomark Res"},{"key":"1833_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.saa.2022.122000","volume":"286","author":"Q Zeng","year":"2023","unstructured":"Zeng Q, Chen C, Chen C, Song H, Li M, Yan J, et al. Serum raman spectroscopy combined with convolutional neural network for rapid diagnosis of HER2-positive and triple-negative breast cancer. Spectrochim Acta A Mol Biomol Spectrosc. 2023;286:122000.","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"1833_CR52","doi-asserted-by":"publisher","DOI":"10.2174\/0115680096388071250527074008","author":"MS Hussain","year":"2025","unstructured":"Hussain MS, Zhang L, Ashique S. Extracellular Vesicles-Associated tRFs as Emerging Biomarkers in Breast Cancer. Curr Cancer Drug Targets. 2025. https:\/\/doi.org\/10.2174\/0115680096388071250527074008.","journal-title":"Curr Cancer Drug Targets"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01833-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01833-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01833-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:02:47Z","timestamp":1772625767000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-026-01833-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1833"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01833-8","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of Peking Union Medical College Hospital (approval number: ZS-2834). Informed consent forms were obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}